ArticlePulmonary therapy2025
Overlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?
Article in Pulmonary therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Beyond the Lungs: Cardiovascular Risk in COPD Patients with a History of Tuberculosis-A Narrative Review.Journal of clinical medicine · 2026Review
- COPD-OSA overlap syndrome: inflammatory and oxidative stress mechanisms, biomarkers, and clinical implications.Frontiers in medicine · 2026Review
- Global Research Landscape and Clinical Hotspots in COPD-OSA Overlap Syndrome: A Bibliometric and Visualization Analysis.International journal of chronic obstructive pulmonary disease · 2026Review
- Diagnosis and Management of Overlap Syndrome (COPD-OSA): Evidence, Challenges and Prospects.Nature and science of sleep · 2026Review
- The value of cough sound monitoring via an audio-enabled smartwatch for OSA screening in COPD patients: a cross-sectional exploratory study.Frontiers in medicine · 2025Article
- Advancing towards personalized medicine: Practical specifications for management of treatable traits in patients with COPD exacerbations.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity. While several studies have previously focused on the role of triple therapy in patients with COPD, none of these has examined the potential benefits of this treatment in patients with COPD and concomitant OSA. Moreover, it is unknown whether patients with OS should be treated with triple therapy starting from their initial assessment, since they represent a population at risk for future exacerbations, in comparison to patients with COPD alone. In this commentary, we discuss these issues and highlight the need for further studies regarding the role of triple therapy in outcomes for patients with OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.